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Rep
ona,Fludarabine and lenalidomide are essential drugs in the front-line treatment of non-Hodgkin lymphoma
(NHL) and multiple myeloma (MM), respectively. Data suggests that fludarabine and lenalidomide therapy
may have a deleterious effect on stem cell mobilization. In the European compassionate use program, 48 pa-
tients (median age 57 years) previously treated with fludarabine (median 5 cycles; range: 1-7 cycles) were
given plerixafor plus granulocyte colony-stimulating factor (G-CSF) for remobilization following a primary
mobilization attempt. The overall median number of CD341 cells collected was 2.3  106/kg (range:
0.3-13.4). The minimum required number of CD341 cells ($2.0  106/kg) was collected from 58% of
patients in a median of 2 days. Thirty-five patients (median age5 57 years) previously treated with lenalido-
mide (median 5 cycles; range: 1-10 cycles) were given plerixafor plus G-CSF for remobilization. The overall
median number of CD341 cells collected was 3.4 106/kg (range: 1.1-14.8). The minimum required number
of CD341 cells ($2.0 106 per kg) was collected from 69% of patients in a median of 2 days. In conclusion,
salvage mobilization with plerixafor plus G-CSF is successful in the majority of patients with MM previously
treated with lenalidomide. In fludarabine-exposed patients, only 58% of patients will achieve successful
salvage mobilization with plerixafor plus G-CSF, suggesting the need for novel mobilization regimens
algorithms in this subgroup of patients.
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High-dose chemotherapy with or without radio-
therapy followed by autologous hematopoietic stem
cell transplantation (HSCT) is an effective treatment
for patients with non-Hodgkin lymphoma (NHL)
[1,2] and multiple myeloma (MM) [3]. At present,
granulocyte colony-stimulating factor (G-CSF)-mobi-
lized peripheral blood stem cells are the preferred stemtre Hospitalier et Universitaire (CHU) de Nantes,
ematologie Clinique, Nantes, Universite de Nantes,
Investigation Clinique en Cancerologie (CI2C),
CRNCA UMR 892, Nantes, France; 2University
of Hamburg-Eppendorf, Hamburg, Germany;
College London, Department of Haematology,
nited Kingdom; 4Department of Internal Medicine
ty Hospital of Cologne, Germany; 5Department of
y, Oncology & Internal Diseases, Medical Univer-
arsaw, Warsaw, Poland; 6HPC Transplant Pro-
eatson West of Scotland Cancer Centre, Glasgow,
gdom; 7Hospitais da Universidade, Coimbra, Portu-
ava University Hospital, Zagreb, Croatia; 9Internı
ologicka klinika Lekarske Fakulty MU a FN Brno,
ublic; 10Cremona Hospital, Section of Hematology,
Italy; 11Department of Hematology and Oncologicalcell source for autologous HSCT [4]. The success of
HSCmobilization is usually assessed by the total num-
ber of CD341 stem cells collected, with a cutoff of 2.0
 106 CD341 cells/kg recipient body weight being
considered as a minimum requirement for transplant.
Higher cell dose in the range of 4-5  106 CD341
cells/kg, however, are associated with faster neutro-
phils and platelets recovery [5]. Traditionally, HSCSciences ‘‘L&A Seragnoli,’’ Institute of Hematology, University
of Bologna, Bologna, Italy; 12St. Laszlo Hospital, Department
of Haematology & SCT, Budapest, Hungary; 13Algemeen
Ziekenhuis Sint-Jan, Brugge, Belgium; 14Medical University
of Vienna, Austria; and 15Catalan Institute of Oncology,
IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
Financial disclosure: See Acknowledgments on page 316.
*These two authors share senior authorship.
Correspondence and reprint requests: MohamadMohty, MD, PhD,
Hematologie Clinique, CHUdeNantes, Place A. Ricordeau, F-
44093 Nantes Cedex, France (e-mail: mohamad.mohty@
univ-nantes.fr).
Received August 2, 2011; accepted October 1, 2011
 2012 American Society for Blood and Marrow Transplantation
1083-8791/$36.00
doi:10.1016/j.bbmt.2011.10.003
Biol Blood Marrow Transplant 18:309-329, 2012 315Plerixafor after Fludarabine/Lenalidomidemobilization has been achieved using G-CSF alone or
in combination with chemotherapy, with a failure rate
reported in 5% to 30% of cases [6]. The main risk fac-
tors for failure or suboptimal mobilization are ad-
vanced age (.60 years), progressive disease, bone
marrow involvement, or previous chemotherapy
including drugs such as fludarabine [7] or lenalidomide
[8]. Indeed, given the increasing use of fludarabine as
part of the treatment armamentarium of different
lymphoma subtypes, and the wide use of lenalidomide
in MM treatment regimens, collection of adequate
numbers of autologous CD341 stem cells in patients
who are candidates for autologous HSCT is becoming
a matter of concern [9]. Plerixafor (previously
AMD3100) reversibly and selectively antagonizes the
CXCR4 chemokine receptor resulting in mobilization
of CD341 cells to the peripheral blood [10]. Before the
drug approval in Europe, a plerixafor compassionate
use program (CUP) was available from July 2008 to
August 2010 to provide access to the drug for patients
with MM or lymphoma who had previously failed
a mobilization attempt, and who were not eligible for
another specific plerixafor trial. In this report, we pres-
ent the efficacy data of plerixafor in a subgroup of
patients in the CUP who were previously treated
with fludarabine or lenalidomide.PATIENTS AND METHODS
From June 2008 to August 2010, over 1400 pa-
tients were enrolled in the European CUP, and
a European Consortium for Stem Cell Collection
(ECOSM) collected data in one-half of patients
treated. Eligibility criteria for the CUP were age
.18 years, a diagnosis of NHL, Hodgkin’s disease,
or MM, and candidate for autologous HSCT but
who had previously failed to collect a minimum of
2.0  106 CD341 cells/kg or did not even proceed to
apheresis based on a low peripheral blood CD341
count (usually\10 cells/mL) after a conventional mo-
bilization procedure. The current analysis focused on
83 patients included in this CUP who were previously
treated with fludarabine or lenalidomide (for at least 1
treatment course including fludarabine or lenalido-
mide) before autologous stem cell collection, and for
whom adequate data for analysis were available. All
patients signed informed consents for inclusion in
the CUP and for collection of their data.
The salvage mobilization protocol included non-
pegylated G-CSF, administered at a dose of 10 mg/kg
daily by subcutaneous injection on 4 consecutive
days. In the evening of the fourth day, patients received
subcutaneous plerixafor at a dose of 240 mg/kg. Apher-
esis was usually initiated on the fifth day, 10 to 12 h af-
ter plerixafor and 1 h after G-CSF administration.Apheresis and daily administration of G-CSF and pler-
ixafor were continued until the patient collected
enough CD341 cells for auto-HSCT (minimum of
2.0  106/kg), and a maximum of 7 plerixafor injec-
tions was allowed. The apheresis procedures were per-
formed according to the standard protocols at each
institution.
Theprimary endpoint for the current analysiswas to
assess the rate of successful mobilization defined as col-
lection of a total number$2.0 106 CD341 cells/kg of
body weight. Descriptive statistics were used to define
characteristics of patients.RESULTS AND DISCUSSION
This retrospective analysis included a total of
83 patients. Patients’ characteristics and mobilization
features are summarized in Table 1. A total of 48 pa-
tients were previously treated with fludarabine (‘‘Flu
group’’), whereas 35 patients received lenalidomide
(‘‘Len group’’). All 48 patients from the ‘‘Flu group’’
had a diagnosis of NHL, whereas all patients from
the ‘‘Len group’’ hadMM. In the Flu group, the overall
median number of CD341 cells collected after salvage
mobilization with plerixafor was 2.3  106/kg (range:
0.3-13.4). Of the 48 patients, 28 (58%) reached the
minimum number of 2.0  106 CD341 cells/kg,
whereas only 3 patients (6%) collected $5.0  106
CD341 cells. The collection target of 2.0  106/kg
was reached in a median of 2 apheresis sessions (range:
1-3).
The overall median number of CD341 cells col-
lected in the Len group was 3.4  106/kg (range:
1.1-14.8). Among these 35 patients, 24 patients
(69%) collected the minimum number of CD341 cells
($2.0  106/kg), including 12 patients (34%) who
were able to collect $5.0  106 cells/kg. In the Len
group, 7 patients (20%) had received a prior autolo-
gous HSCT before salvage mobilization with plerixa-
for. Both targets were reached with a median of 2
apheresis sessions (range: 1-4).
In this salvage CUP program, 58% of patients pre-
viously exposed to fludarabine successfully mobilized
$2.0  106 CD341 cells/kg using plerixafor plus
G-CSF, among them only 3 patients (6%) were able
to collect an optimal graft of $5.0  106 CD341/kg,
allowing for at least 2 HSCT procedures. Interest-
ingly, previously published data suggested that first-
line mobilization success rates in patients pretreated
with fludarabine can range from 46% to 63% [11-13]
with G-CSF alone, G-CSF plus chemotherapy, or
G-CSF plus stem cell factor. Furthermore, second-
line mobilization regimens are considered to be of
little effect in this subgroup of patients [14,15].
Therefore, results observed in the current analysis in
Table 1. Study Population Characteristics
Characteristic (%)
Fludarabine
(n 5 48)
Lenalidomide
(n 5 35)
Patient age, median (range) 57 (36-69) 57 (34-66)
Patient gender
Male 26 (54) 18 (51)
Female 22 (46) 17 (42)
Fludarabine or lenalidomide cycles,
median (range)
5 (1-7) 5 (1-10)
Diagnosis and disease status
NHL 48 (100) 0
Multiple myeloma 0 35 (100)
Previous chemotherapy: number of lines,
median (range)
3 (1-6) 4 (1-9)
Previous autograft
Yes 0 7 (20)
No 43 (90) 20 (57)
Data missing 5 (10) 8 (23)
Radiotherapy
Yes 5 (10) 3 (9)
No 36 (75) 24 (68)
Data missing 7 (15) 8 (23)
Mobilization strategy with plerixafor
Steady-state G-CSF mobilization 38 (79) 27 (77)
Chemotherapy + G-CSF mobilization 10 (21) 8 (23)
No. of patients collected 44 (92) 34 (97)
CD34+ cells collected/kg, median (range) 2.3 (0.3-13.4) 3.4 (1.1-14.8)
No. of patients who reached
$2.106 CD34+
28 (58) 24 (69)
No. of apheresis days to reach
$2.106 CD34+
2 (1-3) 2 (1-4)
No. of patients who reached
$5.106 CD34+
3 (6) 12 (34)
No. of apheresis days to reach
$5.106 CD34+
2 (1-3) 2 (1-3)
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However, one cannot ignore that nearly one-half of
fludarabine-treated patients failed to be rescued after
salvage remobilization with plerixafor, raising the issue
of the use of this drug as front-line therapy in order to
optimize the overall results in this subgroup predicted
to be very poor mobilizers and thus improve treatment
options [9].
In contrast, in patients previously treated with
lenalidomide, salvage remobilization with plerixafor
plus G-CSF was significantly more effective with 69%
of the 38 patients successfully mobilizing $2.0  106
CD341 cells/kg, including 34% of cases achieving
$5.0 106 CD341 cells/kg. In the literature, mobiliza-
tion failure rates in patients pretreated with lenalido-
mide ranged from 7% to 45% [8,16,17], suggesting
that second-line agents are likely to be needed for
these patients. In patients with MM, chemotherapy-
based mobilization has been shown to be effective for
remobilization, especially in patients treatedwith lenali-
domide but at the cost of increased toxicity [17]. Results
from this current analysis after lenalidomide therapy are
comparable to the results published by Micallef et al.
[18] as part of the U.S. CUP, who reported, in 40 pa-
tients previously treated with lenalidomide undergoing
a remobilization attempt after primarymobilization fail-
ure, achievement of the minimum required number ofCD341 cells in 80%. With this background, the
International Myeloma Working Group recently
published comprehensive recommendations for stem
cell mobilization in patients with MM in the era of
novel therapeutic agents. In patients treated with
lenalidomide-based regimens, collection of autologous
stem cells is recommended within the first 4 cycles. In
case of failure of the front-line collection procedure
using G-CSF, second-line collection with G-CSF plus
plerixafor is 1 of the recommended options [19].
In terms of postautologous HSCT outcome, the
design of this CUP-based analysis did not allow assess
to such data, especially engraftment kinetics. How-
ever, based on previously published data [20], it has
already been well established that engraftment features
when using autologous CD341 stem cells mobilized
with G-CSF and plerixafor are at least as good as those
of patients transplanted with stem cells mobilized
without plerixafor.
In conclusion, the majority of patients treated
with lenalidomide can undergo successful salvage
second-line mobilization with plerixafor plus G-CSF.
However, in patients treated with fludarabine, results
are less appealing in the salvage setting,warranting larger
prospective studies evaluating the efficacy of plerixafor
for front-line mobilization in this subgroup of patients.ACKNOWLEDGMENTS
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